Document is current

Article History

Accepted: 24 February 2024

First Online: 6 March 2024

Declarations

:

: This manuscript comprises data from three separate randomized clinical trials with evinacumab. For each clinical trial, the study protocol including all amendments were reviewed and approved by the appropriate institutional review board or independent ethics committee at each participating study site. All trials were conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.

: All patients provided written informed consent prior to enrolment in the clinical trials that are reported in this manuscript.

: This manuscript does not contain any patient identifiable data, therefore consent for publication is not required.

: Robert S. Rosenson reports grants and/or personal fees outside the submitted work from Regeneron Pharmaceuticals, Inc., Amgen, Arrowhead, Avilar Therapeutics, CRISPR Therapeutics, Kowa, Lilly, Lipigon, Merck, Novartis, Precision BioSciences, UpToDate, UltraGenyx, and Verve Therapeutics; and reports stock holdings in MediMergent, LLC.Daniel J. Rader reports consultancy fees/honoraria for scientific advisory board participation for Alnylam, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Verve Therapeutics; and has ownership interest/partnership/principal in Staten Bio and Vascular Strategies.Shazia Ali, Poulabi Banerjee, Jennifer McGinniss, and Robert Pordy are employees of and shareholders in Regeneron Pharmaceuticals, Inc.